Improving Outcomes for Youth OUD Treatment

Friday, April 25, 2025

10:30 AM – 11:45 AM

Presenter(s)

Marc Fishman, MD

Medical Director
Maryland Treatment Centers
Johns Hopkins University School of Medicine
Baltimore, Maryland
Sivabalaji Kaliamurthy, MD, FASAM

Physician
Children's National/Howard University
Washington, District of Columbia
KW

Kevin R. Wenzel, PhD

Psychologist and Director of Research
Maryland Treatment Centers
Baltimore, Maryland

The opioid crisis has devastating consequences for youth and their families, but despite the evidence, uptake of MOUD, treatment capacity, adherence, retention are all remarkably worse for youth than for mature adults. This session will describe several developmentally-informed approaches to improve OUD outcomes in youth with a particular emphasis on MOUD adherence and retention.

Learning Objectives:

Learners will be able to:

Identify barriers to MOUD adherence and retention for youth
Describe the benefits of XR-MOUD in improving adherence for youth
Describe the benefits of assertive approaches to youth MOUD treatment

Disclosure(s):

Marc Fishman, MD: Alkermes: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Braeburn Pharmaceuticals: medication for research studies (Ongoing); Drug Delivery LLC: Consultant/Advisory Board (Ongoing); Indivior: Consultant/Advisory Board (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Nirsum Labs: Consultant/Advisory Board (Ongoing); USWorld Meds: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Sivabalaji Kaliamurthy, MD FASAM: No financial relationships to disclose

Kevin R. Wenzel, PhD: Indivior, Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)